Administration of ONS Based on Purple Sweet Potato in Head and Neck Cancer Patients With Radiotherapy
Effect of Local Food-Based Oral Nutritional Supplements (ONS) Containing Immunonutrients in the Form of Anthocyanin and Omega-3 on Nutritional Status and Inflammatory Response in Head and Neck Cancer Patients Receiving Radiotherapy
1 other identifier
interventional
58
1 country
1
Brief Summary
The goal of this clinical trial is to compare the effect of local food-based oral nutritional supplements (ONS) containing immunonutrients (omega-3 and anthocyanins) on nutritional status and inflammatory response in head and neck cancer patients receiving radiotherapy. The main questions it aims to answer are:
- Is there any effect of local food-based oral nutritional supplements (ONS) containing immunonutrients (omega-3 and anthocyanins) on the nutritional status?
- Is there any effect of local food-based oral nutritional supplements (ONS) containing immunonutrients (omega-3 and anthocyanins) on inflammatory response? Participants will participants will receive ONS in powder form ready to brew as much as 2 servings per day for 3 weeks. Researchers will compare the effect of giving ONS containing immunonutrients compared to standard ONS to see the effect on nutritional status and inflammatory response
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Mar 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 15, 2022
CompletedFirst Submitted
Initial submission to the registry
February 6, 2023
CompletedFirst Posted
Study publicly available on registry
February 23, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2023
CompletedFebruary 24, 2023
February 1, 2023
1.1 years
February 6, 2023
February 22, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
weight change
The differences in body weight after and before the intervention was given. Weight in kilograms will be measured with digital scales Omron Type HBF 378.
immediately after the intervention
Body mass index (BMI)
Calculation of nutritional status using the ratio of body weight (kg) to height squared (m2), where body weight is measured using an digital scales Omron Type HBF 378 and height is measured with a stadiometer.
immediately after the intervention
mid-upper arm circumference (MUAC)
the circumference of the left upper arm, measured at the mid-point between the tip of the shoulder and the tip of the elbow (olecranon process and the acromion). MUAC is measured using a metline in centimeters.
immediately after the intervention
handgrip strength
a simple and reliable measurement of maximum voluntary muscle strength, that is measured with handgrip dynamometer in kilograms (kg) unit.
immediately after the intervention
Study Arms (2)
immunonutrients ONS
EXPERIMENTALthe intervention group received ONS which contained immunonutrients (omega 3 and anthocyanin)
standard ONS
ACTIVE COMPARATORthe control group received standard ONS (isocaloric)
Interventions
1 serving of ONS immunonutrients which is 57 grams of ready-to-brew powder yields 200 ml of a liquid formula containing 251 kcal energy (1.26 kcal/ml), 9 grams protein (14%), 94 mg omega-3, and 20 mg anthocyanins.
1 serving of standard ONS which is 57 grams of ready-to-brew powder yields 200 ml of liquid formula containing 258 kcal energy (1.26 kcal/ml), 5 g (7.5%) protein , 7 g (24%) fat, 43 g (68%) carbohydrate
Eligibility Criteria
You may qualify if:
- Participant diagnosed with advanced stage head and neck cancer (stages 3 and 4) who received radiotherapy, both as concurrent and adjuvant or chemoradiotherapy
- Participant aged 18-80 years
- Participant can consume food, either through a nasogastric tube (NGT) or orally
You may not qualify if:
- Participant has a milk or egg allergy
- Participant with comorbid renal impairment and/or diabetes mellitus
- Participant with poor nutritional status with BMI \< 17.0 kg/m2
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Brawijayalead
- Gadjah Mada Universitycollaborator
Study Sites (1)
dr. Sardjito General Hospital
Yogyakarta, DI Yogyakarta, 55284, Indonesia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Fuadiyah Nila, MPH
Gadjah Mada University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- University of Brawijaya
Study Record Dates
First Submitted
February 6, 2023
First Posted
February 23, 2023
Study Start
March 15, 2022
Primary Completion
April 30, 2023
Study Completion
May 30, 2023
Last Updated
February 24, 2023
Record last verified: 2023-02